GlassScriptPhysician profile
Michael V Tran
NPI 1285652578
$2,784.08
in general payments reported to CMS, 2019-2025
24 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $220 · 2021: $54.82 · 2022: $77.15 · 2023: $283 · 2024: $660 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrosurface Incorporated | $1,231.09 | 2019 | |
| Endo USA, INC. | $193.50 | 2024 | |
| Paratek Pharmaceuticals, INC. | $151.85 | 2022-2025 | Nuzyra |
| Convatec INC. | $149.92 | 2024 | |
| Bone Support INC. | $149.66 | 2024 | Ceramentbone Void Filler, Cerament G |
| Zyla Life Sciences, INC. | $143.93 | 2019-2020 | |
| Smith+Nephew, INC. | $132.59 | 2019-2024 | Grafix Pl |
| Horizon Therapeutics Plc | $128.11 | 2023 | Krystexxa |
| Amgen INC. | $124.61 | 2024-2025 | Krystexxa |
| Trice Medical, INC. | $79.00 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.01 | 2023 | Jublia |
| Orthofix Medical, INC. | $37.52 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $34.90 | 2024 | |
| Kci USA, INC. | $32.30 | 2023 | Activ.A.C. |
| Ibsa Pharma INC. | $22.89 | 2023 | Tirosint, Licart |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ermi LLC | $20.10 | 2019 | |
| Melinta Therapeutics, LLC | $19.92 | 2019 | |
| Maruho Medical, INC. | $17.86 | 2020 | |
| Nevro Corp. | $14.83 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.07 | 2022 | |
| Organogenesis INC. | $12.78 | 2021 | |
| Merck Sharp & Dohme LLC | $11.88 | 2019 | |
| Assertio Therapeutics, INC. | $9.76 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.